JP2023523218A5 - - Google Patents
Info
- Publication number
- JP2023523218A5 JP2023523218A5 JP2022563971A JP2022563971A JP2023523218A5 JP 2023523218 A5 JP2023523218 A5 JP 2023523218A5 JP 2022563971 A JP2022563971 A JP 2022563971A JP 2022563971 A JP2022563971 A JP 2022563971A JP 2023523218 A5 JP2023523218 A5 JP 2023523218A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- cancer
- weeks
- storage
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063013801P | 2020-04-22 | 2020-04-22 | |
| US63/013,801 | 2020-04-22 | ||
| PCT/IB2021/053254 WO2021214658A1 (en) | 2020-04-22 | 2021-04-20 | Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523218A JP2023523218A (ja) | 2023-06-02 |
| JP2023523218A5 true JP2023523218A5 (enExample) | 2024-04-30 |
Family
ID=75639945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022563971A Pending JP2023523218A (ja) | 2020-04-22 | 2021-04-20 | ヘテロ二量体ヒトインターロイキン－１５（ｈｅｔＩＬ－１５）の医薬組成物及び医薬製品 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210330747A1 (enExample) |
| EP (1) | EP4138782A1 (enExample) |
| JP (1) | JP2023523218A (enExample) |
| KR (1) | KR20230004655A (enExample) |
| CN (1) | CN115443127A (enExample) |
| AR (1) | AR122428A1 (enExample) |
| AU (1) | AU2021260989A1 (enExample) |
| BR (1) | BR112022020973A2 (enExample) |
| CA (1) | CA3178895A1 (enExample) |
| CO (1) | CO2022014867A2 (enExample) |
| IL (1) | IL297326A (enExample) |
| MX (1) | MX2022013352A (enExample) |
| TW (1) | TW202214290A (enExample) |
| WO (1) | WO2021214658A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117024749A (zh) | 2019-06-28 | 2023-11-10 | 国立大学法人东京大学 | 蛋白质内包高分子胶束 |
| TWI857396B (zh) * | 2021-11-18 | 2024-10-01 | 大陸商山東先聲生物製藥有限公司 | Il-15突變體融合蛋白藥物組合物 |
| IL322075A (en) * | 2023-02-14 | 2025-09-01 | Akron Bioproducts Llc | Pharmaceutical compositions of interleukin for use in vivo |
| CN117883565A (zh) * | 2023-12-25 | 2024-04-16 | 中山大学 | 沙美特罗和pd-1抗体联用在制备治疗黑色素瘤的药物中的应用 |
| WO2025206413A1 (en) * | 2024-03-28 | 2025-10-02 | The University Of Tokyo | Protein-enclosing polymeric complexes |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| EP3263581B2 (en) | 2005-05-17 | 2025-07-09 | University of Connecticut | Compositions and methods for immunomodulation in an organism |
| NZ569541A (en) | 2006-01-13 | 2012-05-25 | Us Gov Health & Human Serv | Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells |
| CN101743249B (zh) | 2007-05-11 | 2017-08-08 | 阿尔托生物科学有限公司 | 融合分子与il‑15变异体 |
| CA2711984A1 (en) * | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
| CA2727953C (en) | 2008-08-22 | 2017-05-16 | Magna Seating Inc. | Disc recliner with reduced backlash |
| US8915886B2 (en) * | 2009-10-21 | 2014-12-23 | Owen Mumford Limited | Autoinjector |
| US8507222B2 (en) | 2010-09-21 | 2013-08-13 | Altor Bioscience Corporation | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
| EP3292873B1 (en) * | 2013-02-22 | 2019-05-01 | CureVac AG | Combination of vaccination and inhibition of the pd-1 pathway |
| ES2811974T3 (es) * | 2014-07-29 | 2021-03-15 | Novartis Ag | Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones |
| WO2017177063A1 (en) * | 2016-04-06 | 2017-10-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of heterodimeric il-15 in adoptive cell transfer |
| WO2019019998A1 (zh) * | 2017-07-25 | 2019-01-31 | 江苏恒瑞医药股份有限公司 | 一种il-15蛋白复合物药物组合物及其用途 |
| EP3810171B1 (en) * | 2018-06-22 | 2025-07-09 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
| JP2022530130A (ja) * | 2019-04-26 | 2022-06-27 | ルビウス セラピューティクス， インコーポレイテッド | 除核赤血球細胞を含む緩衝組成物 |
-
2021
- 2021-04-20 TW TW110114219A patent/TW202214290A/zh unknown
- 2021-04-20 JP JP2022563971A patent/JP2023523218A/ja active Pending
- 2021-04-20 AU AU2021260989A patent/AU2021260989A1/en active Pending
- 2021-04-20 CN CN202180030326.7A patent/CN115443127A/zh active Pending
- 2021-04-20 US US17/234,914 patent/US20210330747A1/en active Pending
- 2021-04-20 WO PCT/IB2021/053254 patent/WO2021214658A1/en not_active Ceased
- 2021-04-20 IL IL297326A patent/IL297326A/en unknown
- 2021-04-20 MX MX2022013352A patent/MX2022013352A/es unknown
- 2021-04-20 CA CA3178895A patent/CA3178895A1/en active Pending
- 2021-04-20 KR KR1020227040050A patent/KR20230004655A/ko active Pending
- 2021-04-20 EP EP21720852.9A patent/EP4138782A1/en active Pending
- 2021-04-20 BR BR112022020973A patent/BR112022020973A2/pt unknown
- 2021-04-22 AR ARP210101082A patent/AR122428A1/es unknown
-
2022
- 2022-10-19 CO CONC2022/0014867A patent/CO2022014867A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023523218A5 (enExample) | ||
| KR102864931B1 (ko) | 인간화 항-전립선 특이적 막 항원(psma) 항체 약물 접합체 | |
| ES2633453T3 (es) | Constructos de fusión de dominios líticos y métodos de preparación y utilización de los mismos | |
| ES2872964T3 (es) | Inmunoconjugado de IL-12 | |
| CN111328346B (zh) | 基于人铁蛋白和蛋白酶可切割肽的融合蛋白及其作为化学治疗载体的用途 | |
| JP2020522494A5 (enExample) | ||
| ES3031307T3 (en) | Proteins binding nkg2d, cd16 and egfr | |
| JP2020138981A5 (enExample) | ||
| ES2773103T3 (es) | Formulación de anticuerpos anti HER2 | |
| ES2526219T3 (es) | Procedimientos de tratamiento de cáncer usando una inmunotoxina | |
| BR112021002278A2 (pt) | proteínas que ligam nkg2d, cd16 e um antígeno associado a tumor | |
| JP2005508981A5 (enExample) | ||
| JP2010047601A (ja) | カハラリドｆ | |
| JP2009521206A5 (enExample) | ||
| RU2017146657A (ru) | Пролекарства, содержащие коньюгат гиалуроновой кислоты, ликера и и двойного агониста glp-1глюкагона | |
| US20110124564A1 (en) | Nucleolin-binding peptides, nucleolin- binding lytic peptides, fusion constructs and methods of making and using same | |
| KR20230010221A (ko) | 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도 | |
| JP2019509311A5 (enExample) | ||
| ES2674491T3 (es) | Nuevos fragmentos de anticuerpos, composiciones y usos de los mismos | |
| JP7660523B2 (ja) | アルカリリン酸塩に基づいた癌治療 | |
| WO2024153224A1 (zh) | 一种含艾日布林衍生物药物偶联物的药物组合物 | |
| CN103347514A (zh) | Fgfr1胞外域组合疗法 | |
| JP2011506436A (ja) | 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法 | |
| EP3996680B1 (en) | Stable formulations of recombinant proteins | |
| JP2023553561A (ja) | Ｇｌｐ－１／ｇｌｐ－２デュアルアゴニストの医薬組成物 |